Curated News
By: NewsRamp Editorial Staff
August 21, 2024
InMed Pharmaceuticals Confirms INM-901 Oral Formulation for Alzheimer's Treatment
Discuss on Reddit
Discuss on SubstackTLDR
- INM-901 confirms significant advantages in oral delivery over intraperitoneal delivery for Alzheimer's treatment.
- INM-901 is a proprietary small molecule drug candidate that maintains similar drug exposure and therapeutic levels in the brain.
- INM-901's oral formulation provides a therapeutic approach with potential to benefit patients in the treatment of Alzheimer's.
- Recent data from preclinical studies confirms the potential of INM-901 as an oral delivery method for Alzheimer's treatment.
Impact - Why it Matters
This news matters as it highlights a potential breakthrough in the treatment of Alzheimer's disease, offering hope for new treatment alternatives to patients. The confirmation of INM-901 as an oral formulation with similar drug levels in the brain tissue compared to intraperitoneal delivery could significantly impact the development of cannabinoid-based pharmaceutical drugs.
Summary
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced the confirmation of INM-901 as an oral formulation for the treatment of Alzheimer's disease. The data from preclinical studies showed that the oral delivery method offers potential advantages such as lower treatment delivery costs.
Michael Woudenberg, InMed’s COO and SVP of CMC, expressed excitement over the potential of INM-901, highlighting the similar drug levels in the target tissue between oral and IP delivery. The company is dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. It is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, InMed Pharmaceuticals Confirms INM-901 Oral Formulation for Alzheimer's Treatment
